Intelligencia, a New York-based AI-driven software platform for pharmaceutical and biotechnology companies to improve the drug development process and reduce risk, raised $12M in Series A funding.
The round was led by MTIP with participation from existing investors Big Pi Ventures and Synetro Group, as well as ZS.
The proceeds from this round will expand Intelligencia’s R&D team in Athens, grow its sales and customer success teams in the US and in Europe, as well as allow it to work even more closely with customers and partners as they seek to incorporate their private/proprietary data into the company’s models.
Co-founded by Dimitrios Skaltsas and Vangelis Vergetis, Intelligencia is an AI-driven technology company that focuses on minimizing the risk of drug development for R&D and Business Development executives to assess the risk of clinical development programs and enables them to make more informed and data-driven decisions as they evaluate their own pipelines and/or external opportunities.
With a focus on R&D productivity, the company’s platform allows customers to:
- assess the probability of success of pipeline drugs, with supporting rationale;
- Unlock the optimal trial design, with comprehensive benchmarks linked to clinical trial success;
- Identify and prioritize additional potential indications to explore for each asset;
- Guide business development decisions by objectively comparing the attractiveness of external assets, based on a variety of features, including the underlying biology, clinical and regulatory data, and company characteristics; and
- Identify emerging technologies and scientific breakthroughs to gain competitive insights and enable identification of “the next big thing” early.
The company currently employs more than 40 people across its headquarters in New York and the R&D center in Athens, Greece.
FinSMEs
12/08/2021